Assessing CI Trends - the facts behind the stats

Inga Kreiensiek & Adèle Groyer
Presentation overview

• Background to the study

• Challenges
  – Why it’s not as simple as fitting a trend line through data

• Examples
  – Effect of changes in heart attack diagnosis
  – Effect of Cardiovascular Screening Programme on risk factors for heart attack
  – Effect of screening for cancer
Background to the study

• UK CI market
  – Association of British Insurers (ABI) standard definitions
  – Many policies sold with fully guaranteed premiums

• Conditions studied
  – Cancer (major sites, each considered separately)
  – Heart attack
  – Stroke
  – Coronary Artery Bypass Graft
  – Multiple Sclerosis
  – Benign Brain Tumour
  – Kidney Failure
Challenges

• Availability and suitability of data
  Examples:
  – Insufficient insured lives data so use population data
  – Availability of first ever-incidence data

• Features reflected by data and different future circumstances
  Examples:
  – Observed trends but risk factors not well understood
  – Changes in diagnostic methods (past and future)
Changes in heart attack diagnosis
What is a heart attack?

The death of a portion of the heart muscle as a result of inadequate blood supply as evidenced by:

- an episode of typical chest pain
- new electrocardiograph changes;

and by

- the elevation of cardiac enzymes.

The evidence must be consistent with the diagnosis of heart attack.

Source: ABI SOBP for CI Cover 1999

Similar to the classic World Health Organisation definition

Source: Wikipedia Commons
… depends on who and when you ask

Medical advances

Mid 1960s:
CK and later CK-MB measurement

Early 1990s:
Evolution of cardiac troponin assays

Clinical heart attack definition

1979:
WHO criteria for diagnosis of MI

2000:
Heart attack redefined - criteria now include elevated troponin levels

2007:
New universal heart attack definition

ABI heart attack definition

1999 SoBP CI
Original heart attack criteria

Revision 2002
Allowed troponin increase as evidence

Revision 2006
Minimum troponin level requirement e.g. cTnT > 1.0 ng/ml
Trends in diagnosed heart attacks

- Improvements driven by improving risk factors
- Similar trend pattern for females
Trends in diagnosed heart attacks (cont.)

- Deteriorations:
  - More cases classified as heart attack with increased use of troponin
  - More recurrent heart attacks in older ages
Adoption of troponin in the UK
MINAP survey 2006
Troponin versus CK measurement in hospitals in England and Wales, 2000 and 2006

Insured lives versus general population

- Insurance vs clinical definition of heart attack
  - Need to adjust for severity criteria in CI definitions

- Changes in smoker prevalence
  - Need to derive trends for insured non-smokers and smokers separately (smoking model)
Cardiovascular screening programme
Vascular screening in the UK

- Announced 2008
- Started April 2009
- Now called NHS Health Check
- All aged 40 – 74
- Rolled out over 3 years

*Putting prevention first – Vascular Checks: Risk assessment and management, published April 2008, DOH*
Good identification and management of risk factors should reduce heart attack rates.
Screening for cancer
Cancer screening in the UK

• FORMAL
  – Breast cancer *started 1988*
    • Mammogram every 3 years for women aged 50 to 70
    • Was 50 to 64 pre-2003 and will be extended to 47 to 73
  – Cervical cancer *started 1988*
    • Pap smear every 3 to 5 years for women aged 25 to 64
  – Bowel cancer *started 2006*
    • Faecal Occult Blood test every 3 years for men and women aged 60 to 69 (Scotland aged 50 to 69)

• INFORMAL
  – Prostate cancer
    • Digital rectal exam and/or PSA blood test
What screening does to cancer incidence

- Accelerates diagnosis of cancer
  - “lead time”
- Diagnoses more cases of cancer
  - “over-diagnosis” some of which is linked to lead time
- Possibly reduces number of cancers
  - by detecting pre-malignant tissue which can be removed
  - e.g. bowel polyps, cervical abnormalities
Hypothetical screening programme model

- 2-year screening cycle between ages 50 and 70
- 100% take-up rate
- 100% sensitivity in detecting cancer with a 2-year lead time
- 10% over-diagnosis rate
  - after adjusting for lead time and survival by cohort
- Preventative element ignored
Incidence shape: before screening is introduced
Incidence shape: established screening programme

![Incidence rate per 100k population vs Age graph]

- **Pre-screening**
- **Established screening with 2-year lead time**
Incidence shape: established screening programme

- Pre-screening
- Established screening with 2-year lead time
- Plus 10% lead-time adjusted overdiagnosis rate
Incidence shape: “prevalent” rounds of screening programme
Incidence shape: “prevalent” rounds of screening programme
Incidence shape: “prevalent” rounds of screening programme
Example: Breast cancer

Age-specific incidence Great Britain

Source: Cancer Research UK
Example: Breast cancer

Age-specific incidence Great Britain

Source: Cancer Research UK
Example: Breast cancer

Age-specific incidence Great Britain

Source: Cancer Research UK
Screening models in practice: When are they used?

• Modelling changes to existing screening programmes
  – e.g. breast cancer
• Modelling introduction of new programmes
  – e.g. bowel cancer
• Modelling possible introduction of new programmes
  – e.g. prostate cancer
Conclusion

• Projection of CI trends is important

• Heart attack
  – Adjust base rate to allow for increased diagnosis using troponin
  – Future improving trend mostly because of NHS Health Check

• Cancer screening
  – Breast & Bowel cancer: adjustments to current and future base rates
  – Prostate cancer: increasing trend for informal screening increase to base rate for possible formal screening
This presentation is protected by copyright. All the information contained in it has been very carefully researched and compiled to the best of our knowledge. Nevertheless, no responsibility is accepted for its accuracy, completeness or currency. In particular, this information does not constitute legal advice and cannot serve as a substitute for such advice. It may not be duplicated or forwarded without the prior consent of the Gen Re.